Vaccinia virus (ATCC® VR-2034)

Classification: Poxviridae, Orthopoxvirus  /  Product Format: frozen

Classification Poxviridae, Orthopoxvirus
Agent Vaccinia virus
Strain S-variant
Applications
Vaccination recommended for lab staff manipulating vaccinia, monkeypox, or cowpox viruses (CDC/NIH Biosafety in Microbiological and Biomedical Laboratories, 4th ed, 1999 - stock no.
Biosafety Level 2
Isolation
The small variant isolated from strain WR (ATCC VR-119).
The small variant isolated from strain WR (ATCC VR-119).
Product Format frozen
Storage Conditions -70°C
Comments
The small variant isolated from strain WR (ATCC VR-119).
Vaccination recommended for lab staff manipulating vaccinia, monkeypox, or cowpox viruses (CDC/NIH Biosafety in Microbiological and Biomedical Laboratories, 4th ed, 1999 - stock no. 017-040-00547-4).
Effect on Host
Cytopathic effects in tissue culture
Recommended Host
HeLa cells (ATCC CCL-2); CV-1 cells (ATCC CCL-70)
Growth Conditions
Incubation: 5 days
Effect on Host
Cytopathic effects in tissue culture
Name of Depositor New York State Department of Health
References

Paoletti E, Panicali D. Modified vaccinia virus. US Patent 4,603,112 dated Jul 29 1986

Paoletti E, Panicali D. Method for immunizing animals with synthetically modified vaccinia virus. US Patent 4,722,848 dated Feb 2 1988

Panicali D, et al. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J. Virol. 37: 1000-1010, 1981. PubMed: 6262520